These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 20840664)

  • 21. Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men.
    Killick E; Morgan R; Launchbury F; Bancroft E; Page E; Castro E; Kote-Jarai Z; Aprikian A; Blanco I; Clowes V; Domchek S; Douglas F; Eccles D; Evans DG; Harris M; Kirk J; Lam J; Lindeman G; Mitchell G; Pachter N; Selkirk C; Tucker K; Zgajnar J; Eeles R; Pandha H
    Sci Rep; 2013; 3():2059. PubMed ID: 23792811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers.
    Cremers RG; Eeles RA; Bancroft EK; Ringelberg-Borsboom J; Vasen HF; Van Asperen CJ; ; Schalken JA; Verhaegh GW; Kiemeney LA
    Urol Oncol; 2015 May; 33(5):202.e19-28. PubMed ID: 25746941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2.
    Roed Nielsen H; Petersen J; Therkildsen C; Skytte AB; Nilbert M
    Acta Oncol; 2016; 55(1):38-44. PubMed ID: 26360800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate cancer screening in BRCA and Lynch syndrome mutation carriers.
    Castro E; Goh CL; Eeles RA
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initial Findings from a High Genetic Risk Prostate Cancer Clinic.
    Sessine MS; Das S; Park B; Salami SS; Kaffenberger SD; Kasputis A; Solorzano M; Luke M; Vince RA; Kaye DR; Borza T; Stoffel EM; Cobain E; Merajver SD; Jacobs MF; Milliron KJ; Caba L; van Neste L; Mondul AM; Morgan TM
    Urology; 2021 Oct; 156():96-103. PubMed ID: 34280438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
    Shimada S; Yoshida R; Nakashima E; Kitagawa D; Gomi N; Horii R; Takeuchi S; Ashihara Y; Kita M; Akiyama F; Ohno S; Saito M; Arai M
    Breast Cancer; 2019 Nov; 26(6):846-851. PubMed ID: 30980249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.
    Gallagher DJ; Gaudet MM; Pal P; Kirchhoff T; Balistreri L; Vora K; Bhatia J; Stadler Z; Fine SW; Reuter V; Zelefsky M; Morris MJ; Scher HI; Klein RJ; Norton L; Eastham JA; Scardino PT; Robson ME; Offit K
    Clin Cancer Res; 2010 Apr; 16(7):2115-21. PubMed ID: 20215531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The clinical impact of genetic susceptibility to prostate cancer.
    Bratt O
    Eur Urol; 2014 Sep; 66(3):500-1. PubMed ID: 24702982
    [No Abstract]   [Full Text] [Related]  

  • 29. Subgroups of familial and aggressive prostate cancer with considerable frequencies of BRCA2 mutations.
    Maier C; Herkommer K; Luedeke M; Rinckleb A; Schrader M; Vogel W
    Prostate; 2014 Oct; 74(14):1444-51. PubMed ID: 25111659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations.
    Agalliu I; Gern R; Leanza S; Burk RD
    Clin Cancer Res; 2009 Feb; 15(3):1112-20. PubMed ID: 19188187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.
    Lecarpentier J; Silvestri V; Kuchenbaecker KB; Barrowdale D; Dennis J; McGuffog L; Soucy P; Leslie G; Rizzolo P; Navazio AS; Valentini V; Zelli V; Lee A; Amin Al Olama A; Tyrer JP; Southey M; John EM; Conner TA; Goldgar DE; Buys SS; Janavicius R; Steele L; Ding YC; Neuhausen SL; Hansen TVO; Osorio A; Weitzel JN; Toss A; Medici V; Cortesi L; Zanna I; Palli D; Radice P; Manoukian S; Peissel B; Azzollini J; Viel A; Cini G; Damante G; Tommasi S; Peterlongo P; Fostira F; Hamann U; Evans DG; Henderson A; Brewer C; Eccles D; Cook J; Ong KR; Walker L; Side LE; Porteous ME; Davidson R; Hodgson S; Frost D; Adlard J; Izatt L; Eeles R; Ellis S; Tischkowitz M; ; Godwin AK; Meindl A; Gehrig A; Dworniczak B; Sutter C; Engel C; Niederacher D; Steinemann D; Hahnen E; Hauke J; Rhiem K; Kast K; Arnold N; Ditsch N; Wang-Gohrke S; Wappenschmidt B; Wand D; Lasset C; Stoppa-Lyonnet D; Belotti M; Damiola F; Barjhoux L; Mazoyer S; ; Van Heetvelde M; Poppe B; De Leeneer K; Claes KBM; de la Hoya M; Garcia-Barberan V; Caldes T; Perez Segura P; Kiiski JI; Aittomäki K; Khan S; Nevanlinna H; van Asperen CJ; ; Vaszko T; Kasler M; Olah E; Balmaña J; Gutiérrez-Enríquez S; Diez O; Teulé A; Izquierdo A; Darder E; Brunet J; Del Valle J; Feliubadalo L; Pujana MA; Lazaro C; Arason A; Agnarsson BA; Johannsson OT; Barkardottir RB; Alducci E; Tognazzo S; Montagna M; Teixeira MR; Pinto P; Spurdle AB; Holland H; ; Lee JW; Lee MH; Lee J; Kim SW; Kang E; Kim Z; Sharma P; Rebbeck TR; Vijai J; Robson M; Lincoln A; Musinsky J; Gaddam P; Tan YY; Berger A; Singer CF; Loud JT; Greene MH; Mulligan AM; Glendon G; Andrulis IL; Toland AE; Senter L; Bojesen A; Nielsen HR; Skytte AB; Sunde L; Jensen UB; Pedersen IS; Krogh L; Kruse TA; Caligo MA; Yoon SY; Teo SH; von Wachenfeldt A; Huo D; Nielsen SM; Olopade OI; Nathanson KL; Domchek SM; Lorenchick C; Jankowitz RC; Campbell I; James P; Mitchell G; Orr N; Park SK; Thomassen M; Offit K; Couch FJ; Simard J; Easton DF; Chenevix-Trench G; Schmutzler RK; Antoniou AC; Ottini L
    J Clin Oncol; 2017 Jul; 35(20):2240-2250. PubMed ID: 28448241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation.
    Willems AJ; Dawson SJ; Samaratunga H; De Luca A; Antill YC; Hopper JL; Thorne HJ;
    Clin Cancer Res; 2008 May; 14(10):2953-61. PubMed ID: 18445692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer.
    Akbari MR; Wallis CJ; Toi A; Trachtenberg J; Sun P; Narod SA; Nam RK
    Br J Cancer; 2014 Sep; 111(6):1238-40. PubMed ID: 25101567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of targeted screening for prostate cancer: introducing the IMPACT study.
    Mitra AV; Bancroft EK; Eeles RA;
    BJU Int; 2007 Jun; 99(6):1350-5. PubMed ID: 17419707
    [No Abstract]   [Full Text] [Related]  

  • 35. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.
    Oh M; Alkhushaym N; Fallatah S; Althagafi A; Aljadeed R; Alsowaida Y; Jeter J; Martin JR; Babiker HM; McBride A; Abraham I
    Prostate; 2019 Jun; 79(8):880-895. PubMed ID: 30900310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population.
    Lavie O; Narod S; Lejbkowicz F; Dishon S; Goldberg Y; Gemer O; Rennert G
    Ann Oncol; 2011 Apr; 22(4):964-966. PubMed ID: 20924075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [What management for the asymptomatic men carriers of BRCA1 or 2 mutation? Results of a survey in the French oncogenetic centers].
    Brachot-Simeonova I; Morin G; Gillaux C; Demeer B; Gondry J; Mathieu M; Fauvet R
    Bull Cancer; 2012 Apr; 99(4):417-23. PubMed ID: 22429936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ambiguity in a masculine world: Being a BRCA1/2 mutation carrier and a man with prostate cancer.
    Psychooncology; ; . PubMed ID: 28812325
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.